查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1534942

氣喘：市場洞察、流行病學和預測（2024-2032）

Asthma Disease - Market Insight, Epidemiology, & Forecast (2024-2032F)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 155 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預期氣喘市場在預測期內（2024-2032年）將成長約 5%。全球氣喘盛行率的增加是由於環境因素、過敏原和生活方式的改變推動了氣喘市場的成長。此外，針對氣喘控制的新藥和生物製劑的研究和開發取得進展。例如，2023年2月，Pulmatrix啟動了PUR1900治療過敏性支氣管肺麴菌病（ABPA）和氣喘的首例患者2b期研究。這項全球研究將在 16 週內評估安全性、耐受性和有效性，並將支持 Pulmatrix 和 Cipla 的合作夥伴關係，預計在2024年中期為氣喘患者提供治療。

根據已上市藥物，市場包括TEZSPIRE、TRELEGY ELLIPTA、ARNUITY ELLIPTA、CINQAIR（reslizumab）、FASENRA（benralizumab）、DUPIXENT（dupilumab）、NUCALA（mepolizumab）、AIRSUPRA（albuterol、budesonide）、XOLAIR（omalizumab）。其中，TEZSPIRE將在2023年佔據較大佔有率。 TEZSPIRE 是作為治療嚴重氣喘的藥物而銷售的，它為儘管採用標準治療但仍無法控制氣喘的患者提供了一種新的有效的治療選擇，成為氣喘市場的主要驅動力。其獨特的作用機制針對並抑制胸腺基質淋巴細胞生成素（TSLP），這是氣喘發炎的關鍵驅動因素，對各種類型的嚴重氣喘具有廣泛的療效。 TEZSPIRE 的開發滿足了治療需求，有助於改善患者狀況並減少病情加重的次數。該療法不僅將擴大治療方法的範圍，還將透過增加醫生對新醫療產品的使用以及增加對呼吸系統疾病創新生物製劑的開發投資來推動市場的發展。

為了更了解氣喘疾病的市場採用情況，根據 7MM 在美國、德國、英國、法國、義大利、西班牙和日本等國家的市場情況進行了分析。到2023年，美國將佔據壓倒性的市場佔有率。由於氣喘盛行率高且醫療負擔高，美國氣喘市場規模相當大。例如，美國成年人氣喘盛行率從2001年的6.9%上升到2021年的8.0%。越來越多的人意識到並診斷出氣喘以及治療方案的改進是推動市場擴張的因素。新型治療劑的存在，包括與普通吸入器和片劑合併使用的生物製劑，可以改善間歇性和嚴重氣喘的控制。對減少空氣污染和加強現有結構的醫療設施和技術創新的需求也將刺激市場，政府和公司對藥品生產的大力投資也將刺激市場。

市場上營運的主要公司包括AstraZeneca, GSK plc, Cipla, Teva Pharmaceutical Industries Ltd., Sanofi, Avillion LLP, Novartis AG, CHIESI Farmaceutici S.p.A., Boehringer Ingelheim International GmbH, AB Science等。

目錄

第1章 市場介紹

  • 市場定義
  • 主要目的
  • 利害關係人
  • 限制

第2章 研究方法或前提

  • 調查過程
  • 調查方法
  • 受訪者簡介

第3章 執行摘要

  • 行業概況
  • 依細分市場進行預測
    • 市場成長強度
  • 區域展望

第4章 市場動態

  • 促進因素
  • 機會
  • 抑制因素
  • 趨勢

第5章 疾病背景與概論

  • 簡介
  • 分類
  • 原因
  • 風險因素
  • 徵兆和症狀
    • 早期徵兆和症狀
    • 症狀的進展
  • 診斷
    • 身體檢查
    • 肺功能測試

第6章 治療

  • 第一線治療：吸入性皮質類固醇（ICS）
  • 支氣管熱成形術
  • 抗發炎
  • 伴隨藥物
  • 抗膽鹼能藥物
  • 生物製品
  • 抗生素
  • 其他
  • 新興療法
    • 免疫治療
    • 其他

第7章 病人旅程

第8章 氣喘指引

  • NICE 氣喘管理建議
  • 英國氣喘管理指南
  • 嚴重氣喘定義、評估和治療的國際 ERS/ATS 指南
  • 其他氣喘指南

第9章 流行病學與病患人數，2022-2032年

  • 假設和理由
  • 7MM氣喘流行病學
    • 7MM中氣喘患者總數
    • 病例取決於氣喘的嚴重程度
    • 嚴重氣喘類型的病例
    • 依年齡劃分的氣喘患者人數（7MM）

第10章 氣喘流行病學：依國家分類

  • 美國
    • 7MM中氣喘患者總數
    • 病例取決於氣喘的嚴重程度
    • 嚴重氣喘類型的病例
    • 依年齡劃分的氣喘患者人數（7MM）
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 日本

第11章 氣喘市場洞察、上市藥物

  • TEZSPIRE（tezepelumab-ekko）：Amgen/AstraZeneca
    • 藥物簡介
    • 監理結果
    • 其他開發活動
    • 臨床開發
    • 安全性和有效性
  • TRELEGY ELLIPTA (fluticasone furoate/umeclidinium/vilanterol)：GlaxoSmithKline
  • ARNUITY ELLIPTA (fluticasone furoate inhalation powder)：GlaxoSmithKline
  • CINQAIR (reslizumab)：Teva Pharmaceutical
  • FASENRA (benralizumab)：AstraZeneca
  • DUPIXENT (dupilumab)：Sanofi and Regeneron Pharmaceutical
  • NUCALA (mepolizumab)：GlaxoSmithKline (GSK)
  • AIRSUPRA (albuterol and budesonide)：AstraZeneca/Avillion
  • XOLAIR (omalizumab)：Novartis

第12章 氣喘市場洞察、新藥

  • GSK3511294 (Depemokimab)：GlaxoSmithKline
    • 藥物簡介
    • 臨床開發
    • 安全性和有效性
  • Givinostat：Italfarmaco
  • Masitinib (AB07105)：AB Science
  • PT010：AstraZeneca
  • Dexpramipexole Dihydrochloride：Areteia Therapeutics
  • PBF-680：Palobiofarma SL/Pivotal S.L.
  • ARS 1：ARS Pharmaceuticals, Inc.
  • MEDI3506 (tozorakimab)：AstraZeneca
  • AZD1402 (PRS-060)：Pieris Pharma/AstraZeneca
  • Atuliflapon (AZD5718)：AstraZeneca
  • Amlitelimab：Sanofi

第13章 氣喘市場：7MM 分析

  • 主要發現
  • 2022-2032年氣喘總市場規模 7MM
  • 依已上市藥物劃分的氣喘市場規模為 7MM
  • 以新藥劃分的氣喘市場規模為 7MM
  • 2022-2032年美國市場規模
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 日本

第14章 未滿足的需求

第15章 競爭態勢

  • 主要競爭對手 - 已上市藥品
  • 主要競爭對手 - III 期藥品
  • 主要競爭對手 - II 期藥品

第16章 公司簡介

  • AstraZeneca
  • GSK plc
  • Cipla
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Avillion LLP
  • Novartis AG
  • CHIESI Farmaceutici S.p.A.
  • Boehringer Ingelheim International GmbH
  • AB Science

第17章 首字母縮寫與先決條件

第18章 附錄

簡介目錄
Product Code: UMHE212941

The asthma market refers to the market for products that are used to address this condition through the creation, manufacturing, and sale of drugs, devices, and therapies that help control and treat asthma, a long-term illness that results in inflammation of airways and constriction of the bronchi. There is a growing focus on respiratory diseases and the development of new treatments wherein the growth of the market is attributed to the increasing incidences of asthma, the growing awareness among people about respiratory wellness, and the emerging options in the form of new inhalers and biologics. Also, there are more favorable governmental policies and higher consumer demand for individualized treatment, which complements conceptions of therapy adherence and results in better asthma management market trends.

The asthma market is expected to grow around ~5% during the forecast period (2024-2032). The Increasing incidence of asthma globally is due to environmental factors, allergens, and lifestyle changes that drive the growth of the asthma market. Also, ongoing research and development of new drugs and biologics targeting asthma control. For instance, in February 2023, Pulmatrix initiated a Phase 2b trial, dosing the first patient with PUR1900 for Allergic Bronchopulmonary Aspergillosis (ABPA) and asthma. The global study will assess safety, tolerability, and efficacy over 16 weeks, supporting Pulmatrix's collaboration with Cipla to bring therapy to patients with asthma, with proof-of-concept data expected by mid-2024.

Based on the marketed therapies, the market has been divided into TEZSPIRE, TRELEGY ELLIPTA, ARNUITY ELLIPTA, CINQAIR (reslizumab), FASENRA, (benralizumab), DUPIXENT (dupilumab), NUCALA (mepolizumab), AIRSUPRA (albuterol and budesonide), and XOLAIR (omalizumab). Among them, the TEZSPIRE held a significant market share in 2023. TEZSPIRE, a marketed therapy for severe asthma, is significantly driving the asthma market by offering a novel and effective treatment option for patients with uncontrolled asthma despite standard therapies. Its unique mechanism of action targets and inhibits thymic stromal lymphopoietin (TSLP), a key driver of asthma inflammation, providing broader efficacy across various types of severe asthma. The development of TEZSPIRE responds to a therapeutic need and contributes to the enhancement of the patient's status and the decrease in the number of exacerbations. Besides broadening the therapeutic approach, this therapy contributes to market development by increasing the use of new medical products by physicians and increasing investment in the development of innovative biologicals for respiratory diseases.

For a better understanding of the market adoption of asthma disease, the market is analyzed based on its 7MM presence in countries such as The U.S., Germany, the UK, France, Italy, Spain, and Japan. The U.S. held a dominant share of the market in 2023. The U.S. market for asthma diseases is substantial, driven by the high prevalence and significant healthcare burden of the disease. For instance, the current asthma prevalence among adults in the U.S. increased from 6.9% in 2001 to 8.0% in 2021. Larger populations aware and diagnosed, coupled with improved treatment choices, are the factors that help in the expansion of the market. The presence of novel treatment, including biologics, in combination with the common inhalers and tablets improves the control of both intermittent and severe asthma. The demand for healthcare facilities and innovations to decrease air pollution and enhance existing structures along with strong investment in pharmaceutical production by governments and companies also stimulate the market.

Some of the major players operating in the market include AstraZeneca, GSK plc, Cipla, Teva Pharmaceutical Industries Ltd., Sanofi, Avillion LLP, Novartis AG, CHIESI Farmaceutici S.p.A., Boehringer Ingelheim International GmbH, and AB Science.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Asthma Market
  • 2.2. Research Methodology of the Asthma Market
  • 2.3. Respondent Profile

3.EXECUTIVE SUMMARY

  • 3.1. Industry Synopsis
  • 3.2. Segmental Outlook
    • 3.2.1. Market Growth Intensity
  • 3.3. Regional Outlook

4.MARKET DYNAMICS

  • 4.1. Drivers
  • 4.2. Opportunity
  • 4.3. Restraints
  • 4.4. Trends

5.DISEASE BACKGROUND AND OVERVIEW

  • 5.1. Introduction
  • 5.2. Classification
  • 5.3. Causes
  • 5.4. Risk Factors
  • 5.5. Signs and Symptoms
    • 5.5.1. Early Signs and Symptoms
    • 5.5.2. Progressed Symptoms
  • 5.6. Diagnosis
    • 5.6.1. Physical exam
    • 5.6.2. Lung Function Tests

6.TREATMENT

  • 6.1. First Line Treatment - Inhaled corticosteroids (ICS)
  • 6.2. Bronchial Thermoplasty
  • 6.3. Anti-inflammatory
  • 6.4. Combination Medicines
  • 6.5. Anticholinergics
  • 6.6. Biologics
  • 6.7. Antibiotics
  • 6.8. Others
  • 6.9. Emerging Therapies
    • 6.9.1. Immunotherapy
    • 6.9.2. Others

7.PATIENT JOURNEY

8.GUIDELINES ON ASTHMA

  • 8.1. NICE Recommendations for Asthma Management
  • 8.2. British Guidelines on the Management of Asthma
  • 8.3. International ERS/ATS Guidelines on the Definition, Evaluation, and Treatment of Severe Asthma
  • 8.4. Other Guidelines for Asthma

9.EPIDEMIOLOGY & PATIENT POPULATION, 2022-2032F

  • 9.1. Assumptions and Rationale
  • 9.2. Epidemiology of Asthma in 7MM
    • 9.2.1. Total Prevalent Population of Asthma in the 7MM
    • 9.2.2. Severity-specific cases of Asthma
    • 9.2.3. Type-specific cases of Severe Asthma
    • 9.2.4. Age-specific Prevalent Population of Asthma in the 7MM

10.EPIDEMIOLOGY OF ASTHMA BY COUNTRY

  • 10.1. The United States
    • 10.1.1. Total Prevalent Population of Asthma in the 7MM
    • 10.1.2. Severity-specific cases of Asthma
    • 10.1.3. Type-specific cases of Severe Asthma
    • 10.1.4. Age-specific Prevalent Population of Asthma in the 7MM
  • 10.2. Germany
  • 10.3. UK
  • 10.4. France
  • 10.5. Italy
  • 10.6. Spain
  • 10.7. Japan

11.ASTHMA MARKET INSIGHTS, MARKETED THERAPIES

  • 11.1. TEZSPIRE (tezepelumab-ekko): Amgen/AstraZeneca
    • 11.1.1. Drug Profile
    • 11.1.2. Regulatory Achievements
    • 11.1.3. Other Development Activities
    • 11.1.4. Clinical Development
    • 11.1.5. Safety and Efficacy
  • 11.2. TRELEGY ELLIPTA (fluticasone furoate/umeclidinium/vilanterol): GlaxoSmithKline
  • 11.3. ARNUITY ELLIPTA (fluticasone furoate inhalation powder): GlaxoSmithKline
  • 11.4. CINQAIR (reslizumab): Teva Pharmaceutical
  • 11.5. FASENRA (benralizumab): AstraZeneca
  • 11.6. DUPIXENT (dupilumab): Sanofi and Regeneron Pharmaceutical
  • 11.7. NUCALA (mepolizumab): GlaxoSmithKline (GSK)
  • 11.8. AIRSUPRA (albuterol and budesonide): AstraZeneca/Avillion
  • 11.9. XOLAIR (omalizumab): Novartis

Complete List in the report

12.ASTHMA MARKET INSIGHTS, EMERGING THERAPIES

  • 12.1. GSK3511294 (Depemokimab): GlaxoSmithKline
    • 12.1.1. Drug Profile
    • 12.1.2. Clinical Development
    • 12.1.3. Safety and Efficacy
  • 12.2. Givinostat: Italfarmaco
  • 12.3. Masitinib (AB07105): AB Science
  • 12.4. PT010: AstraZeneca
  • 12.5. Dexpramipexole Dihydrochloride: Areteia Therapeutics
  • 12.6. PBF-680: Palobiofarma SL/Pivotal S.L.
  • 12.7. ARS 1: ARS Pharmaceuticals, Inc.
  • 12.8. MEDI3506 (tozorakimab): AstraZeneca
  • 12.9. AZD1402 (PRS-060): Pieris Pharma/AstraZeneca
  • 12.10. Atuliflapon (AZD5718): AstraZeneca
  • 12.11. Amlitelimab: Sanofi

Complete List in the report

13.ASTHMA MARKET: 7MM ANALYSIS

  • 13.1. Key Findings
  • 13.2. Total Market Size of Asthma in the 7MM, 2022-2032F
  • 13.3. Market Size of Asthma by Marketed Therapies in the 7MM
  • 13.4. Market Size of Asthma by Emerging Therapies in the 7MM
  • 13.5. United States Market Size, 2022-2032F
    • 13.5.1. Total Market Size of Asthma in the United States
    • 13.5.2. Market Size of Asthma by Marketed Therapies in the United States
    • 13.5.3. Market Size of Asthma by Emerging Therapies in the United States
  • 13.6. Germany
  • 13.7. UK
  • 13.8. France
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. Japan

14.UNMET NEEDS

15.COMPETITIVE LANDSCAPE

  • 15.1. Key Competitors - Marketed Therapies
  • 15.2. Key Competitors - Phase III Drugs
  • 15.3. Key Competitors - Phase II Drugs

16.COMPANY PROFILES

  • 16.1. AstraZeneca
    • 16.1.1. Company Overview
    • 16.1.2. Key Financials
    • 16.1.3. SWOT Analysis
    • 16.1.4. Product Portfolio
    • 16.1.5. Recent Developments
  • 16.2. GSK plc
  • 16.3. Cipla
  • 16.4. Teva Pharmaceutical Industries Ltd.
  • 16.5. Sanofi
  • 16.6. Avillion LLP
  • 16.7. Novartis AG
  • 16.8. CHIESI Farmaceutici S.p.A.
  • 16.9. Boehringer Ingelheim International GmbH
  • 16.10. AB Science

17.ACRONYMS & ASSUMPTION

18.ANNEXURE